Nyxoah S.A. (NYXH)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | 0 | 1 | 3 | 4 | 5 | 10 | 23 | 43 |
| Operating profit | €m | -83 | -87 | ||||||
| Net profit | €m | -12 | -28 | -31 | -43 | -59 | -90 | -98 | -50 |
| EPS reported | € | -2.36 | -2.17 | ||||||
| Operating cashflow per share | € | -1.77 | -1.30 | ||||||
| Capex per share | € | 0.02 | 0.04 | ||||||
| FCF per share | € | -1.79 | -1.34 | ||||||
| Free cash flow | €m | -68 | -74 | ||||||
| Net debt | €m | -7 | -47 | ||||||
| Book value equity | €m | 49 | 83 | ||||||
| Book value per share | € | 1.29 | 1.46 | ||||||
| Number of shares | m | 38.11 | 57.01 | ||||||
| DPS (TTM paid) | € | 0.00 | 0.00 |
Financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 3.04 | 1.80 | ||||||
| P/S LTM | x | 14.89 | 6.59 | ||||||
| P/FCF LTM | x | -2.18 | -2.02 | ||||||
| EV/EBITDA LTM | x | -1.95 | -2.09 | ||||||
| EV/Sales LTM | x | 16.09 | 5.68 | ||||||
| Earnings Yield LTM | % | -60.38% | -1.23% | ||||||
| FCF Yield | % | -45.78% | -49.51% | ||||||
| Quality | |||||||||
| ROE | % | -183.43% | -179.71% | ||||||
| ROIC | % | -88.95% | -59.89% | ||||||
| Operating margin | % | -8.28% | -3.83% | ||||||
| Gross margin | % | +63.13% | +51.31% | ||||||
| FCF/Sales | % | -681.64% | -337.53% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +121.63% | +401.06% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -1.62 | -1.41 | ||||||
| Net Debt/EBITDA | x | -0.15 | 0.15 | ||||||
| EBIT/Net interest | x | -49.05 | -5.73 | ||||||
| Net debt/market cap | % | +27.77% | +36.17% | ||||||
| Net debt/Equity | x | -0.13 | -0.57 | ||||||
| Gross debt/equity | x | 0.86 | 0.63 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free